BusinessCellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.By Nasdaq OMXApr 19, 2016, 12:30 PM UTC
